Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003761 · ClinicalTrials.gov registry record · Phase 1

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

A Phase 1 study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
4
Study locations

NCT00003761 is a Phase 1 study of Breast Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 20 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003761, a Phase 1 study of Breast Cancer, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
4
Study locations

Study Summary

This protocol is designed to evaluate the side effects of rV-DF3/MUC1 and to determine the safest dose which should be used in the treatment of breast cancer.

Conditions Studied

Breast Cancer

Interventions

  • BIOLOGICAL rV-DF3/MUC1

Study Locations (4)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston
  • Boston Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 1999-03-03
Est. Completion 2001-10-19
Phase Phase 1

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00003761

The ClinicalTrials.gov registry entry for NCT00003761 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which rV-DF3/MUC1 is the first listed.

NCT00003761 reports 4 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00003761 about?

NCT00003761 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Breast Cancer". This protocol is designed to evaluate the side effects of rV-DF3/MUC1 and to determine the safest dose which should be used in the treatment of breast cancer.

What is the current status of trial NCT00003761?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 1999-03-03. Estimated completion is 2001-10-19.

What conditions does trial NCT00003761 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00003761?

The interventions under investigation include: rV-DF3/MUC1 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00003761?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003761 being conducted?

This trial has 4 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.